Incidence and Determinants of Spontaneous Seroclearance of Hepatitis B e Antigen and DNA in Patients With Chronic Hepatitis B

Clinical Gastroenterology and Hepatology

Volumn 10, Issue 5, 2012, Pages

  Yang, Hwai I ^a,b,c   Hung, Hsiu Lian ^d   Lee, Mei Hsuan ^c   Liu, Jessica ^c,d   Jen, Chin Lan ^c   Su, Jun ^e   Wang, Li Yu ^f   Lu, Sheng Nan ^g   You, San Lin ^c   Iloeje, Uchenna H ^e   Chen, Chien Jen ^c,d  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c GENOMICS RESEARCH CENTER   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e BRISTOL MYERS SQUIBB   (United States)

^f MACKAY MEDICAL COLLEGE   (Taiwan)

^g CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Epidemiology; Long term Follow up Study; Natural Course; Virology

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; SERODIAGNOSIS; VIRUS LOAD;

EID: 84862813631     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2011.12.019     Document Type: Article

References (29)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004, 11:97-107.
2. Fact sheet: hepatitis B World Health Organization. http://www.who.int/mediacentre/factsheets/fs204/en/index.html.
3. Chen C.J., Wang L.Y., Yu M.W. Epidemiology of hepatitis B virus infection in the Asia-Pacific region. J Gastroenterol Hepatol 2000, 15(Suppl):E3-E6.
4. Custer B., Sullivan S.D., Hazlet T.K., et al. Global epidemiology of hepatitis B virus. J Clin Gastroenterol 2004, 38:S158-S168.
5. Lok A.S., McMahon B.J. Chronic hepatitis B: update 2009. Hepatology 2009, 50:661-662.
6. Chen C.J., Yang H.I., Su J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295:65-73.
7. Lee W.M. Hepatitis B virus infection. N Engl J Med 1997, 337:1733-1745.
8. Liaw Y.F., Chu C.M. Hepatitis B virus infection. Lancet 2009, 373:582-592.
9. Yang H.I., Lu S.N., Liaw Y.F., et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002, 347:168-174.
10. Iloeje U.H., Yang H.I., Su J., et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006, 130:678-686.
11. Iloeje U.H., Yang H.I., Jen C.L., et al. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol 2007, 5:921-931.
12. Chen C.J., Yang H.I. Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol 2011, 26:628-638.
13. Liaw Y.F., Leung N., Kao J.H., et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008, 2:263-283.
14. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009, 50:227-242. European Association for the Study of the Liver.
15. Chen C.J., Iloeje U.H., Yang H.I. Long-term outcomes in hepatitis B: the REVEAL-HBV study. Clin Liver Dis 2007, 11:797-816.
16. Liu J., Yang H.I., Lee M.H., et al. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology 2010, 139:474-482.
17. Ryu S.H., Chung Y.H., Choi M.H., et al. Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study. J Hepatol 2003, 39:614-619.
18. Kao J.H., Chen P.J., Lai M.Y., et al. Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers. J Med Virol 2004, 72:363-369.
19. Chu C.J., Hussain M., Lok A.S. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 2002, 122:1756-1762.
20. Liaw Y.F. Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy. J Gastroenterol Hepatol 2003, 18:246-252.
21. Chu C.M., Liaw Y.F. Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. J Hepatol 2005, 43:411-417.
22. Liaw Y.F. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int 2009, 29(Suppl 1):100-107.
23. Chu C.M., Yeh C.T., Lee C.S., et al. Precore stop mutant in HBeAg-positive patients with chronic hepatitis B: clinical characteristics and correlation with the course of HBeAg-to-anti-HBe seroconversion. J Clin Microbiol 2002, 40:16-21.
24. Tong S.P., Li J.S., Vitvitski L., et al. Active hepatitis B virus replication in the presence of anti-HBe is associated with viral variants containing an inactive pre-C region. Virology 1990, 176:596-603.
25. Santantonio T., Jung M.C., Miska S., et al. High prevalence and heterogeneity of HBV preC mutants in anti-HBe-positive carriers with chronic liver disease in southern Italy. J Hepatol 1991, 13(Suppl 4):S78-S81.
26. Okamoto H., Yotsumoto S., Akahane Y., et al. Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen. J Virol 1990, 64:1298-1303.
27. Liaw Y.F. Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review. Hepatology 2011, 53:2121-2129.
28. Kamatani Y., Wattanapokayakit S., Ochi H., et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 2009, 41:591-595.
29. Zhang H., Zhai Y., Hu Z., et al. Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat Genet 2010, 42:755-758.